Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

USFDA conducts inspection at Cipla's Indore facility

"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.

April 16, 2018 / 09:16 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Cipla today said the US health regulator has conducted an audit at its Indore facility and has not issued any data integrity or repeat observations.

"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.

There were no data integrity and/or repeat observations, it added.

The company, however, did not provide the details of observations it has received.

"At this stage, the company believes the observations are unlikely to have any material adverse impact. The Company will submit the response within the stipulated time frame," Cipla said.

Shares of Cipla Ltd today closed at Rs 583.55 per scrip on BSE, up 5.22 percent from its previous close.

PTI
first published: Apr 16, 2018 09:05 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347